Volume 63, Pages S79-S82 (June 2003)

Slides:



Advertisements
Similar presentations
Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.
Advertisements

Parathyroidectomy: Whom and when?
Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.
Volume 65, Issue 2, Pages (February 2004)
Beta blockers in the management of chronic kidney disease
Iron status and iron supplementation in peritoneal dialysis patients
Anemia management in chronic kidney disease
Volume 64, Pages S72-S77 (November 2003)
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients  Demetrios J. Kutsogiannis, R.T.Noel.
Volume 63, Pages S32-S38 (June 2003)
Parathyroidectomy: Whom and when?
Progression of renal failure and hypertensive nephrosclerosis
Volume 63, Pages S88-S90 (June 2003)
Volume 75, Issue 11, Pages (June 2009)
Volume 76, Pages S50-S99 (August 2009)
Volume 70, Pages S21-S25 (December 2006)
The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age  B.O. Eriksen, O.C. Ingebretsen  Kidney International 
George A. Kaysen, Burl R. Don
A new era in phosphate binder therapy: What are the options?
Volume 78, Pages S33-S36 (August 2010)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
New vitamin D analogs Kidney International
Use of vitamin D in chronic kidney disease patients
Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.
Edmund G. Lowrie  Kidney International 
Study of Heart and Renal Protection (SHARP)
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Aquaporin gene delivery to kidney
Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.
Volume 67, Pages S63-S68 (January 2005)
Volume 74, Pages S88-S93 (December 2008)
Recent experience with high-dose intravenous iron administration
Volume 56, Pages S31-S37 (December 1999)
New insights in uremic toxins
Volume 64, Pages S72-S77 (November 2003)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Nephrology in Latin America, with special emphasis on Brazil
Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia 
AGEs in foods: Do they play a role in uremia?
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
Extracorporeal removal of toxins
Pathogenesis of refractory secondary hyperparathyroidism
Nephrology Crossword: Glomerulonephritis
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Measurement of renal function in pre-ESRD patients
Volume 73, Pages S72-S75 (April 2008)
Volume 74, Pages S60-S63 (December 2008)
Homocysteine, renal function, and risk of cardiovascular disease
Volume 67, Pages S55-S62 (January 2005)
Volume 66, Pages S18-S21 (November 2004)
Volume 74, Issue 8, Pages (October 2008)
Peritoneal dialysis in Mexico
Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program  Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.
Phosphate binders on iron basis: A new perspective?
Volume 70, Pages S84-S90 (November 2006)
Volume 63, Issue 2, Pages (February 2003)
Return to dialysis after renal transplantation
Volume 55, Pages S3-S16 (June 1999)
Charles A. Herzog  Kidney International 
Volume 70, Issue 5, Pages (September 2006)
Volume 56, Issue 1, Pages (July 1999)
Strategies for iron supplementation: Oral versus intravenous
Volume 54, Issue 6, Pages (January 1998)
Evaluation of the Losartan in Hemodialysis (ELHE) Study
Renal vascular disease in the elderly
Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis  Karl-Georg Fischer, M.D., Andreas van.
Volume 55, Pages S41-S46 (June 1999)
Volume 54, Pages S112-S119 (December 1998)
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Volume 63, Pages S79-S82 (June 2003) Advantages of adjusting the initial dose of intravenous calcitriol according to PTH levels  Minerva Rodríguez-García, José Luis Fernández-Martín, Jaime Ruiz De Castañeda, José Hervás-Sánchez, Jorge Benito Cannata- Andía  Kidney International  Volume 63, Pages S79-S82 (June 2003) DOI: 10.1046/j.1523-1755.63.s85.19.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Evolution of PTH after 3 months of treatment in the “compliants” and “noncompliants” in the 3 groups of patients. Gray boxes indicate the limits of PTH considered the goal of the study (125 to 250 pg/mL). The percentage of PTH decrease is shown in parentheses. *P < 0.002 compared with the initial PTH. Kidney International 2003 63, S79-S82DOI: (10.1046/j.1523-1755.63.s85.19.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Percentage of patients reaching the objective of the study (PTH 125 to 250 pg/mL) after 3 months of treatment in the different groups of patients.*P < 0.025 and **P < 0.003, respectively. Kidney International 2003 63, S79-S82DOI: (10.1046/j.1523-1755.63.s85.19.x) Copyright © 2003 International Society of Nephrology Terms and Conditions